Old Web
English
Sign In
Acemap
>
Paper
>
CONTINUED LARGE AMYLOID PET REDUCTIONS AT 36 MONTHS IN THE GANTENERUMAB OPEN-LABEL EXTENSION STUDIES
CONTINUED LARGE AMYLOID PET REDUCTIONS AT 36 MONTHS IN THE GANTENERUMAB OPEN-LABEL EXTENSION STUDIES
2019
Gregory Klein
Paul Delmar
Geoffrey A. Kerchner
Carsten Hofmann
Danielle Abi-Saab
Smiljana Ristic
Sunita Rehal
Nicola Voyle
Monika Baudler
Paulo Fontoura
Rachelle Doody
Keywords:
Internal medicine
Psychiatry
Diabetes mellitus
Amyloid
Psychology
Gantenerumab
open label
Oncology
amyloid pet
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]